A retrospective study of patient outcomes over the first 24-months of treatment with mepolizumab in severe asthma patients
Latest Information Update: 11 Feb 2022
Price :
$35 *
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 11 Feb 2022 New trial record